oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Differences in outcome for cervical cancer patients treated with or without brachytherapy
Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Örebro University, School of Medical Sciences. Department of Oncology.
Örebro University, School of Health Sciences. Department of Oncology.ORCID iD: 0000-0002-5063-631X
2017 (English)In: Brachytherapy, ISSN 1538-4721, E-ISSN 1873-1449, Vol. 16, no 1, 133-140 p.Article in journal (Refereed) Published
Abstract [en]

Purpose: To compare the clinical outcome of cervical cancer patients treated with primary radiotherapy with and without the addition of brachytherapy.

Methods and Materials: In all, 220 patients with cervical cancer stage I-IV treated between 1993 and 2009 were included. Three or five 6.0 Gy fractions of brachytherapy were given in addition to the external beam radiotherapy to 134 patients, whereas 86 patients received external beam radiotherapy alone (EBRTA). In the EBRTA group, the patients received external boost instead of brachytherapy with a total dose to the tumor of 64-72 Gy.

Results: The 5-year overall survival and cancer-specific survival rates of the complete series were 42.5% and 55.5%, respectively. The rates of primary complete remission, 5-year cancer-specific survival, and recurrence were 92.5%, 68.5%, and 31.3% for the brachytherapy group vs. 73.3%, 35.4%, and 37.2% for the EBRTA group. The survival (all types) of the patients receiving brachytherapy was significantly (p < 0.0001) better than for the patients treated with external boost, but the difference was most pronounced in FIGO stage II tumors. Higher FIGO stage, nonsquamous cell carcinoma histology, treatment with EBRTA, and lower total equal 2-Gy (EQD2) external dose were significantly associated with poorer survival, lower rate of remission, and higher recurrence rate in multivariate models.

Conclusions: Primary tumor remission rate, recurrence rate, and all types of survival rates were improved in the brachytherapy group. Brachytherapy is important to achieve sufficient doses to the periphery and central part of the tumor and should always be considered in treatment of cervical carcinomas.

Place, publisher, year, edition, pages
Philadelphia, USA: Elsevier, 2017. Vol. 16, no 1, 133-140 p.
Keyword [en]
Cervical cancer, radiotherapy, external beam radiotherapy, brachytherapy, prognosis
National Category
Cancer and Oncology Radiology, Nuclear Medicine and Medical Imaging
Identifiers
URN: urn:nbn:se:oru:diva-53486DOI: 10.1016/j.brachy.2016.09.011ISI: 000392793900013PubMedID: 27836496Scopus ID: 2-s2.0-85009895081OAI: oai:DiVA.org:oru-53486DiVA: diva2:1046522
Available from: 2016-11-14 Created: 2016-11-14 Last updated: 2017-10-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Dreifaldt, Ann-CharlotteBohr Mordhorst, LouiseSorbe, Bengt
By organisation
School of Medical SciencesSchool of Health Sciences
In the same journal
Brachytherapy
Cancer and OncologyRadiology, Nuclear Medicine and Medical Imaging

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 73 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf